08/08/2013

The Proof of Principle Program Committee at the Canadian Institutes of Health Research (CIHR) is benefitting from the expertise of Dr. Clermont Beaulieu, Director, Business Development in Life Sciences, at Univalor.

CIHR invited Mr. Beaulieu to join the committee after a thorough recruitment process. His competence and excellence in his field attracted CIHR’s attention and earned him the support of his colleagues, who recommended his appointment.

08/08/2013

eValorix (www.evalorix.com/), the Univalor subsidiary that distributes a wide range of university-created products online, officially opened for business in May. A true highway for commercializing university research, eValorix already offers many products developed by leading experts from its partner institutions. Univalor expects that hundreds of educational tools, software products, technical publications and innovative technologies will be added to eValorix’s virtual shelves in the coming months.

18/06/2013

The offensive line of the fight against cancer can now rely on a promising player: Active Cellular Immunotherapy. Cancer immunotherapy is treatment that uses the patient’s own defence—namely, his or her immune system—to destroy cancer cells. Together with surgery, radiotherapy and chemotherapy, immunotherapy is a treatment option to consider.

18/06/2013

For 39 years, Dr. Nabil G. Seidah had the opportunity to stay ahead of the curve  at the Clinical Research Institute of Montreal (IRCM) with his research on convertases—enzymes involved in the breakdown of proteins into smaller active molecules. His extensive knowledge of a family of nine convertases has allowed him to develop new molecules, convertase inhibitors, which may lead to new drugs to fight high cholesterol and many other diseases. To do this, Dr. Seidah has had to develop innovative tools to facilitate and accelerate the development of these promising new drugs.

17/06/2013

This newsletter marks the end of our first season of publishing this new communication tool. It also coincides with the end of Univalor’s fiscal year on June 30.

Pages